A randomized, placebo-controlled, double blind, phase 1 trial of the safety, immunogenicity, and tolerability of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2007
At a glance
- Drugs PF 5212366 (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Wyeth
- 04 Dec 2007 Status changed from in progress to completed.
- 02 Dec 2006 New trial record.